NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)--Synchron, a new U.S. based company dedicated to the development of minimally invasive neuromoducation technologies, today announced the appointment of neurovascular device-industry veteran Martin Dieck as Chairman. Currently focused on the development of the world’s first endovascular neural interface, Synchron is acquiring SmartStent Pty Ltd, an Australian company with IP rights to Stentrode™, an implantable technology that can interpret signals from the brain. The ground-breaking technology is being developed for patients with paralysis, as well as a range of brain pathologies, and to date has received over $4M in grant monies from the U.S. Defense Advanced Research Projects Agency (DARPA), among other sources.
“It is very rewarding to be invited to assist develop this promising innovative technology,” said Martin Dieck, Chairman, Synchron. “Over the past 20 years, I have been fortunate to work alongside many top physicians and engineers to develop some of the most transformative technologies in the neurovascular space. I look forward to working with the Synchron team to establish this new technology platform which may ultimately benefit a wide range of patients.”
Dieck was most recently co-founder and CEO of Lazarus Effect, Inc., a medical device company that developed a novel vascular interventional device designed to treat acute ischemic stroke. The company was purchased by Medtronic for $100 million in September 2015. Previously, Dieck headed up Nfocus Neuromedical, Inc., a developer of neurovascular intravascular devices, and Concentric Medical, Inc., which developed the first cleared device to restore blood flow in patient’s brain vessels following ischemic stroke.
Two of the co-founders of SmartStent will also join Dieck on the Synchron board: Neurologist Thomas J. Oxley, MD PhD, Mount Sinai Hospital, New York and interventional cardiologist Rahul Sharma, MD, Cedars-Sinai Health System, Los Angeles.
Oxley is the lead author of a paper published in Nature Biotechnology in February 2016, which demonstrated that Stentrode is capable of detecting brain signals. Building on the paper’s findings, it is the intent of Synchron to develop this platform for detection and treatment of a range of neurological conditions.
The core technology, Stentrode, was spun out of collaborative research between DARPA and the University of Melbourne, and originally pursued by SmartStent, which is being acquired by Synchron. President Obama recently highlighted the potential benefit of this technology in a video on Discovery’s Science Channel.
Synchron is currently preparing for its first in-human clinical trials of Stentrode.
About Stentrode™
The world’s first endovascular neural
interface, Stentrode™, is a proprietary new technology platform that is
able to interpret brain activity through minimally invasive endovascular
access. The tiny device is implanted next to the brain’s motor cortex
using procedures commonly used for neurovascular stent implantation,
without having to perform open brain surgery. The platform is currently
being developed for patients with paralysis to facilitate control of
external devices such as robotic limbs, computers and exoskeletons by
translating brain activity. Future applications may include the
potential to diagnose and treat a range of brain pathologies, such as
epilepsy, that currently have only limited or highly invasive surgical
options.
About
Synchron, Inc.
Based in
Silicon Valley, Synchron, Inc. an innovative medical device company
focused on the development of minimally invasive neuromoducation
technology solutions, is developing the world’s first endovascular
neural interface, the StentrodeTM. Development of the
Stentrode technology has been previously supported through a grant from
the U.S. Defense Advanced Research Projects Agency (DARPA).